Customize your JAMA Network experience by selecting one or more topics from the list below.
Winn AN, Keating NL, Trogdon JG, Basch EM, Dusetzina SB. Spending by Commercial Insurers on Chemotherapy Based on Site of Care, 2004-2014. JAMA Oncol. 2018;4(4):580–581. doi:10.1001/jamaoncol.2017.5544
The impact of price variation because of the site of care—receiving treatment in a physician office vs a hospital outpatient department (HOPD)—is an important driver of health care spending.1 While patients may receive the same treatment in either setting, insurers typically reimburse payments to HOPDs at a higher rate than to physician offices. Hospitals justify this payment difference because they incur higher overhead costs and treat more medically complex patient populations.1,2
Critics argue that the value of the services provided, rather than overhead expenses, should determine prices.2 In this study, we describe trends in use of and spending for infused cancer chemotherapy in HOPD vs physician office settings from 2004 through 2014 among commercially insured patients.
Create a personal account or sign in to: